RecruitingPhase 2NCT03206060

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Studying Carney-Stratakis syndrome

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Frank I Lin, M.D.
National Cancer Institute (NCI)
Intervention: Lu-177-DOTATATE(drug)
Enrollment: 130 enrolled
Eligibility: 18-100 years · All sexes
Timeline: 2017 – 2030

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03206060 on ClinicalTrials.gov

Other trials for Carney-Stratakis syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT06440122
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)
King's College Hospital NHS Trust

See all trials for Carney-Stratakis syndrome →

← Back to all trials